- Quarter end
- 30 Sep 2024
- the date the book describes
- Filed
- 5 Nov 2026
- latest of these filings; the earliest 12 Nov 2024
- Managers listing it
- 10
- at least, of 95 tracked, among listed positions
- Comparable managers
- 94
- filed both Q2 2024 and Q3 2024; 8 listed it in both
- Shares listed
- 119,160,163
- combined, among listed positions
- Reported value
- $4.9bn
- combined, at the quarter end
1 line marked †. Value as filed implies a price far from other filers'. Each counts in holders and value as filed, and is left out of the net change in shares.
Among the 94 comparable managers: 6 buyers (opened or added shares) and 3 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.
Managers listing GSK in Q3 2024
10 of 10 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Dodge & Cox | 68,087,163 | $2.8bn | 1.57% | Trimmed | -249,975 | 13 Nov 2024 (the filing on sec.gov) |
| Fidelity (FMR LLC) | 29,008,928 | $1.2bn | 0.07% | Added | +2,224,345 | 5 Nov 2026 (the filing on sec.gov) |
| T. Rowe Price Associates Inc | 7,531,788 | $308m | under 0.1% | Trimmed | -2,700,488 | 14 Nov 2024 (the filing on sec.gov) |
| Arrowstreet Capital LP† Value as filed implies a price far from other filers'. | 3,869,499 | $212m | 0.18% | Added | +1,290,752 | 14 Nov 2024 (the filing on sec.gov) |
| Acadian Asset Management LLC | 4,066,187 | $166m | 0.52% | Added | +2,355,935 | 12 Nov 2024 (the filing on sec.gov) |
| Renaissance Technologies LLC | 2,335,493 | $95m | 0.14% | Trimmed | -12,500 | 13 Nov 2024 (the filing on sec.gov) |
| Capital Research Global Investors | 1,754,493 | $72m | under 0.1% | Held | 0 | 13 Nov 2024 (the filing on sec.gov) |
| Schonfeld Strategic Advisors LLC | 1,329,966 | $54m | 0.36% | Added | n.a. | 14 Nov 2024 (the filing on sec.gov) |
| Bridgewater Associates LP | 965,836 | $39m | 0.22% | Added | +500,010 | 13 Nov 2024 (the filing on sec.gov) |
| Quantbot Technologies LP | 210,810 | $8.6m | 0.34% | Added | n.a. | 13 Nov 2024 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- Acadian Asset Management LLCexisting position · 4,066,187 shares now+2,355,935
- Fidelity (FMR LLC)existing position · 29,008,928 shares now+2,224,345
- Arrowstreet Capital LPexisting position · 3,869,499 shares now+1,290,752
- Bridgewater Associates LPexisting position · 965,836 shares now+500,010
Reductions
- T. Rowe Price Associates Incexisting position · 7,531,788 shares now-2,700,488
- Dodge & Coxexisting position · 68,087,163 shares now-249,975
- Renaissance Technologies LLCexisting position · 2,335,493 shares now-12,500
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2022 | 1 | $19m | n.a. | n.a. |
| Q3 2022 | 18 | $3.9bn | n.a. | n.a. |
| Q4 2022 | 18 | $4.9bn | n.a. | n.a. |
| Q1 2023 | 13 | $4.4bn | n.a. | n.a. |
| Q2 2023 | 13 | $4.3bn | n.a. | n.a. |
| Q3 2023 | 16 | $4.5bn | n.a. | n.a. |
| Q4 2023 | 13 | $4.5bn | 6 | 7 |
| Q1 2024 | 13 | $5.3bn | 5 | 7 |
| Q2 2024 | 10 | $4.6bn | 6 | 4 |
| Q3 2024 | 10 | $4.9bn | 6 | 3 |
| Q4 2024 | 13 | $4.9bn | 11 | 2 |
| Q1 2025 | 11 | $6.3bn | 7 | 6 |
| Q2 2025 | 10 | $6.2bn | 8 | 3 |
| Q3 2025 | 11 | $7.5bn | 6 | 5 |
| Q4 2025 | 11 | $8.8bn | 15 | 13 |
| Q1 2026 | 9 | $9.1bn | 9 | 19 |
| Q2 2026 | 11 | $7.5bn | 15 | 12 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GSK, latest filings →Back to the 13F Explorer →